A compound has the following structure (see the formula attached) or a salt acceptable from the drug point of view, or a pharmaceutical solution of a compound or salt acceptable from the drug point of view, wherein a, a 'and a' are independent, O, C = C, r'o N-R. There, R 'and R' may be independent h, amino, nr7cor6, cor6, conr7r8, C1-C6 asphalt or hydroxy (C1-C6 asphalt),R '' may or may not exist, and exists when allowed by Valencia rules, and does not exceed a, a 'and a' 'are or C = O； R0 and R are independent h, Br, Cl, f or C1-C6 tar； R1 is h, C1-C6 tar or hydroxy (C1-C6 tar)；R2 was selected from the group consisting of H, C1-C6 tar, C1-C6 alcox and hydroxy (C1-C6 tar),Phenyl (C1-C6 tar),Thyroid, heteromorphic, heterocyclic, cor6, ocor6, cour6, nr7cor6, conr7r8 and - (CH2) N-W, wherein W is cyanide, hydroxy, c3-c8cyclododecane, so2n7r8 and so2-r9, R9 is C1-C6 tar, c3-c8cyclododecane, heterogeneous or heterogeneous； in each tar, cyclododecane, Aperiodicity or aperiodicity may not be replaced by halogenation, cyanogen, hydroxyl or C1-C6 asphalt； X is c-r3 or N, wherein R3 may be h or C1-C6 asphalt； R4 and R5 may be independent h, amino, C1-C6 asphalt or hydroxi (C1-C6 asphalt)；R6, R7 and R8 (a full executive summary is attached to the request document.)Un compuesto que tiene la siguiente estructura (ver fórmula en imagen adjunta) o una sal de este aceptable desde el punto de vista farmacéutico, o un solvato aceptable desde el punto de vista farmacéutico de un compuesto o una sal aceptable desde el punto de vista farmacéutico, en donde A, A’ y A’’ son independientemente O, C=O, C-R’ o N-R’’, en donde R’ y R’’ pueden ser independientemente H, amino, -NR7COR6, COR6, -CONR7R8, C1-C6 alquilo o hidroxi(C1-C6 alquilo), y R’’ puede estar presente o ausente, y está presente donde las reglas de valencia lo permiten, y en donde no más de uno de A, A’ y A’’ es O o C=O； R0 y R son independientemente H, Br, Cl, F o C1-C6 alquilo； R1 es H, C1-C6 alquilo o hidroxi(C1-C6 alquilo)
